Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab ± FSRT for relapsed glioblastoma after STUPP (Phase II)
ChiCTR2500104431Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivonescimab in glioblastoma (GBM) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Safety and Progression-Free Survival. Started Jun 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2500104431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104431.